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Available online 16 October 2015Evidence-based medicine should be the impetus for delivering
healthcare services. Nevertheless, the application of the evidence in
day-to-day practice is often not ‘straightforward’ as patient-speciﬁc
variables including emotional, physical and social aspects can in-
ﬂuence ﬁnal treatment decisions.
During the 4th Asia Paciﬁc Prostate Cancer Conference, a
multidisciplinary panel including urologists, medical and radiation
oncologists as well as a palliative care expert from around the re-
gion participated in a discussion on several pertinent aspects of
patient care in the management of advanced prostate cancer. The
panel discussion was an engaging forum that allowed the audience
to highlight and debate key patient care issues they face in their
own practice with the expert panel.
Key issues discussed were the role of radiologic monitoring, the
management of bone metastases and pain control as well as
palliative care. In particular, the panel discussion highlighted the
importance of a multidisciplinary approach to patient care.
One of the common issues patients discuss with prostate cancer
clinicians is monitoring for disease progression. Patients with
advanced prostate cancer often ask their doctors ‘Has my disease
come back?’ Even though this is a common concern for patients,
there is great variability in what clinicians in Asia Paciﬁc would
deﬁne as ‘clinical progression’. For some, prostate-speciﬁc antigen
(PSA) rise alone would be considered as progression, while other
clinicians observe for clinical and/or radiographic progression along
with PSA rise. A pre-meeting survey among delegates revealed that* Corresponding authors: Scott Williams (scott.williams@petermac.org) and
Shigeo Horie (shorie@juntendo.ac.jp).
http://dx.doi.org/10.1016/j.prnil.2015.10.005
p2287-8882 e2287-903X75% of themdiagnose disease progression in their practices through
a combination of methods which include evaluating clinical symp-
toms such as pain, fatigue, and appetite, regular PSA tests, and im-
aging. In general, itwas agreed that a combinationof these shouldbe
included in the deﬁnition of progression. There was also some
variation in the duration of radiologic monitoring for metastatic
castrate resistant prostate cancer (mCRPC) patients in the region.
As disease advances, patients with prostate cancer are likely to
experience bone metastases and associated symptoms. The panel
highlighted that the management of patients bone metastases and
pain should incorporate counselling including recommendations
on lifestyle changes.
Palliative care for mCRPC patients was one of the key highlights
of this panel discussion. During the meeting, all delegates were
asked when palliative care would be most appropriate for prostate
cancer patients. Almost two-thirds of delegates (64%) at the
meeting indicated that palliative care support is required when
patients' quality of life is affected by disease progression or treat-
ment side effects. About one-in-ﬁve indicated that patients should
be referred to palliative care when cure is no longer possible, while
ten percent responded that referral should occur when symptom
relief is required.
One study comparing a group of lung cancer patients who un-
derwent early palliative care and standard oncological care, with
another group that only had standard oncological care revealed
signiﬁcantly improved quality of life and fewer incidences of
depressive symptoms inthe former.1Akeyﬁnding fromthisstudywas
that the group which received early palliative care also had longer
median survival. This was despite having fewer patients who under-
went aggressive end-of-life care.1 In view of these beneﬁts, the panel
emphasized that palliative care should be given a higher priority as
partof theoverallmanagementplan formCRPCpatients in this region.
Further to this, there was some discussion on the stigma
associated with the term ‘palliative care’ as many patients in this
region could consider this to be ‘end of life’ care. The panel
encouraged clinicians to instigate a paradigm change associated
with the services offered by the palliative care teams. Panel
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Fig. 1. Levels of multidisciplinary care in institutions represented by respondents who
participated in a digivote survey at the meeting
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in line with the roles of the specialists involved with this service.
In any case, there was agreement that the involvement of sup-
portive and palliative care services should be as early as possible
to improve patient outcomes.
Another important aspect highlighted during this panel dis-
cussion was the integration of a multidisciplinary team consisting
of, among others, urologists, medical and radiation oncologists,
pathologists, palliative care specialists and allied health pro-
fessionals (including specialist nurses, physiotherapists, pharma-
cists). This is to ensure that treatments can be tailored to offer
individual patients the opportunity to receive high quality medical
procedures and access to specialists for counselling, supportive
care, and rehabilitation.
According to a digivote survey of participants present at the
meeting, there is great variability in the levels of multidisciplinary
care for prostate cancer patients across the region (Fig. 1). The
widespread availability and use of multidisciplinary care is
encouraging, and highlights a common goal to have a collaborative
approach to patient care.References
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